10 Most Shorted Biotech Stocks to Buy According to Hedge Funds

Page 6 of 10

5. Travere Therapeutics Inc. (NASDAQ:TVTX)

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds.

On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth quarter earnings report. The company registered U.S. net product sales figures of $126.6 million for the quarter, relative to $73.5 million during the fourth quarter of 2024. This translates into full-year U.S. net product sales of $410.5 million, exhibiting almost 82% year-on-year growth. Such impressive figures were attributable to FILSPARI’s sales growth.

The company reported $2.7 million in net income for the quarter, a significant jump from a net loss of $60.3 million in Q4 2024. Moreover, it held $322.8 million in cash & equivalents and marketable securities balance as of December 31, 2025. This balance is expected to elevate further during the first half of 2026, as the company anticipates a $25 million sales-based milestone payment from Mirum Pharmaceuticals.

On February 6, a couple of weeks prior to the earnings announcement, Piper Sandler increased the price target on Travere Therapeutics Inc. (NASDAQ:TVTX) from $35 to $38. The firm maintained its Neutral rating on the stock, with an adjusted upside potential of almost 40% at the current level. The adjustment came as the firm reviewed and updated its estimates for several commercial companies following several fourth-quarter pre-releases and ahead of the quarterly announcements.

Travere Therapeutics Inc. (NASDAQ:TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney and metabolic diseases. By focusing on conditions with high unmet needs, such as IgA nephropathy and cystinuria, they strive to set new standards of care for patients.

Page 6 of 10